| Literature DB >> 21999624 |
Einar Lindalen1, Leif I Havelin, Lars Nordsletten, Eva Dybvik, Anne M Fenstad, Geir Hallan, Ove Furnes, Oystein Høvik, Stephan M Röhrl.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2011 PMID: 21999624 PMCID: PMC3247878 DOI: 10.3109/17453674.2011.623569
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.Flowchart of the study.
Breakdown of numbers of different combinations of prosthesis components in the reverse hybrid group during the study period
| Combination of cup and stem (reverse hybrid) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Year | Elite/Corail | Titan/Corail | Kronos/Corail | Reflection PE | Exeter/Corail | Charnley/Corail | Exeter/ABG II | Reflection PE | Reflection PE | Total |
| 2000 | 38 | 3 | 3 | 6 | 1 | 6 | 0 | 0 | 0 | 57 |
| 2001 | 43 | 22 | 14 | 13 | 2 | 4 | 0 | 0 | 0 | 98 |
| 2002 | 45 | 46 | 6 | 37 | 3 | 7 | 0 | 0 | 0 | 144 |
| 2003 | 61 | 50 | 9 | 55 | 8 | 2 | 61 | 0 | 0 | 246 |
| 2004 | 83 | 72 | 14 | 63 | 16 | 9 | 50 | 12 | 0 | 319 |
| 2005 | 178 | 79 | 39 | 69 | 10 | 5 | 61 | 37 | 34 | 512 |
| 2006 | 269 | 82 | 66 | 18 | 11 | 14 | 0 | 29 | 49 | 538 |
| 2007 | 365 | 75 | 98 | 26 | 18 | 34 | 0 | 18 | 29 | 663 |
| 2008 | 362 | 113 | 157 | 5 | 28 | 13 | 0 | 16 | 0 | 694 |
| 2009 | 318 | 180 | 121 | 3 | 45 | 11 | 0 | 14 | 0 | 692 |
| Total | 1762 | 722 | 527 | 295 | 142 | 105 | 172 | 126 | 112 | 3963 |
Full brand name: Reflection Cemented All-Poly.
Comparison of different combinations of prosthesis components in the reverse hybrid group
| Brand name cup/stem | Manufacturer cup/stem | N | Revisions | Median follow-up (range) | Mean age (min–max) | % < 60 year | % male | No. of hospitals (max % at hospital) |
|---|---|---|---|---|---|---|---|---|
| Elite/Corail | Landos Depuy/Depuy | 1762 | 40 | 2.6 (0–10) | 60 (21–92) | 48 | 40 | 15 (34%) |
| Titan/Corail | Landos Depuy/Depuy | 722 | 21 | 3.0 (0–9.8) | 63 (27–91) | 36 | 36 | 11 (34%) |
| Kronos/Corail | Landos Depuy/Depuy | 527 | 12 | 1.8 (0–9.7) | 63 (20–92) | 33 | 32 | 4 (83%) |
| RPE | Smith & Nephew/Depuy | 295 | 17 | 5.6 (0–9.9) | 58 (18–90) | 58 | 37 | 11 (35%) |
| Exeter/ ABG II | Stryker | 172 | 6 | 5.4 (1.4–7.0) | 73 (50–88) | 2 | 37 | 2 (82%) |
| RPE | Smith & Nephew/Scanos | 126 | 5 | 3.6 (0–5.6) | 64 (19–91) | 38 | 37 | 2 (97%) |
| Exeter/Corail | Stryker | 142 | 2 | 1.9 (0–9.9) | 64 (19–87) | 35 | 18 | 5 (67%) |
| Charnley/Corail | Depuy/Depuy | 105 | 2 | 2.8 (0.4–9.9) | 58 (21–86) | 61 | 21 | 14 (46%) |
| RPE | Smith & Nephew/Biomet | 112 | 3 | 3.8 (2.5–4.7) | 61 (40–82) | 36 | 33 | 1 (100%) |
Full brand name: Reflection Cemented All-Poly.
Full brand name: Stryker, Osteonics, Howmedica
Full brand name: Scanos Evolutis
Cup/stem combinations in the cemented group. These have been thoroughly described by Espehaug et al. (2009)
| Manufacturer | Number of prostheses | |
|---|---|---|
| Charnley/Charnley | Depuy | 12,192 |
| Exeter/Exeter | Stryker, Osteonics, Howmedica | 6,419 |
| Reflection PE/Spectron | Smith & Nephew | 8,618 |
| Titan/Titan | Landos, Depuy | 2,736 |
| Spectron/ITH | Smith & Nephew | 162 |
| Link IP/Lubinus SP(I,II) | Waldemar Link | 2,203 |
| Contemporary/Exeter | Stryker, Osteonics, Howmedica | 2,707 |
| Kronos/Titan | Landos, Depuy | 1,073 |
| Elite/Titan | Depuy/Landos Depuy | 1,139 |
| Reflection/ITH | Smith & Nephew | 417 |
Details of the characteristics of the uncemented femoral stems used in the reverse hybrid group. 97% had HA coating
| Stem | Material | Shape | Surface | Thickness of HA | Company |
|---|---|---|---|---|---|
| Corail | Ti6A14V | Straight, tapered | Fully HA-coated | 155 µm | DePuy |
| ABG II | Ti alloy | Anatomic | HA-coated proximal, polished distally | 50 µm | Stryker |
| Hactiv | Ti6A14V | Straight, tapered | Fully HA-coated | 155 µm | Evolutis |
| Taperloc | Ti6A14V | Straight, tapered | Without HA in this study, proximal plasma spray coating | Biomet |
Comparison of demographic data for cemented and reverse hybrid THRs, both for total material and for patients aged < 60 years. Comparison of survival (in %) and relative risk (RR) of revision for cemented and reverse hybrid THRs, with all revisions as endpoint, for total material and for patients aged < 60 years
| Total material | Age < 60 years | |||||
|---|---|---|---|---|---|---|
| Cemented | Reverse hybrid | p-value | Cemented | Reverse hybrid | p-value | |
| n | 37,666 | 3,963 | 3,480 | 1,647 | ||
| Revisions | 1,140 | 108 | 135 | 41 | ||
| Median follow-up (range) | 4.7 (0–10) | 2.9 (0–10) | < 0.001 | 5.2 (0–10) | 3.4 (0–10) | < 0.001 |
| Mean age (min–max) | 73 (16–98) | 61 (18–92) | < 0.001 | 54 (16–60) | 52 (18–60) | < 0.001 |
| % < 60 years | 9 | 42 | < 0.001 | 100 | 100 | |
| % male | 29 | 36 | < 0.001 | 36 | 39 | 0.06 |
| Deceased | 5,928 (15.7%) | 104 (2.6%) | 229 (6.6%) | 25 (1.5%) | ||
| Emigrated | 58 (0.2%) | 8 (0.2%) | 21 (0.6%) | 4 (0.4%) | ||
| Missing | 2 | 0 | 0 | 0 | ||
| Alive | 31,678 (84.1%) | 3,851 (97.2%) | 3,230 (92.8%) | 1,618 (98.2%) | ||
| Diagnosis | < 0.001 | < 0.001 | ||||
| Osteoarthritis | 78.6% | 70.9% | 56.6% | 55.9% | ||
| RA/Inflammatory | 3.3% | 4.2% | 8.0% | 6.0% | ||
| Sequelae hip fracture | 8.9% | 5.2% | 7.1% | 4.8% | ||
| Dysplasia | 4.3% | 11.6% | 16.5% | 20.4% | ||
| Perthes' | 0.6% | 2.2% | 3.1% | 4.5% | ||
| Other | 4.4% | 5.9% | 8.7% | 8.4% | ||
| 3-year survival (95%CI) | 97.9 (97.7–98.0) | 97.7 (97.2–98.2) | 98.0 (97.5–98.5) | 98.3 (97.7–99.0) | ||
| 5-year survival (95%CI) | 97.0 (96.8–97.2) | 96.7 (96.0–97.4) | 96.7 (96.0–97.3) | 97.5 (96.6–98.5) | ||
| 7-year survival (95%CI) | 96.0 (95.7–96.2) | 95.6 (94.4–96.7) | 94.9 (94.0–95.9) | 96.2 (94.6–97.8) | ||
| RR | 1 (Reference) | 1.1 (0.9–1.4) | 0.3 | 1 (Reference) | 0.9 (0.6–1.3) | 0.5 |
Chi-squared test.
Non-parametric Mann-Whitney.
RR adjusted for age, sex, and diagnosis.
Figure 2.Cox survival curves. Endpoint was any revision of the implant for the total material. Adjusted for age, sex, and diagnosis. Age: < 50, 50–59, 60–69, 70–79 and > 80. Diagnosis: OA, RA/inflammatory, or other.
Figure 3.Cox survival curves. Endpoint was any revision of the implant. Age < 60 years. Adjustment for age, sex, and diagnosis. Age: <50, 50–60. Diagnosis: OA, RA/inflammatory, or other.